คุณภาพชีวิตของผู้ป่วยธาลัสซีเมียในโรงพยาบาลพระมงกุฎเกล้าที่ได้รับยาขับเหล็กชนิดรับประทาน : Deferiprone

Abstract

Background: Thalassemia is a chronic hereditary disease. The patients with severe disease present with anemiain the first year of life. Supportive treatment such as blood transfusion and iron chelating agent was demonstratedto improve both patient survival and the quality of life. Deferiprone an oral iron chelating agent was recently usedin Thailand and there are no data on the quality of life in these patients. Objective: To study the quality of life inthalassemic patients treated with Deferiprone. Methods: Descriptive study was conducted using the PedQLTMGeneric Core Scales questionnaires (Thai version) in thalassemic patients at Hematology Unit Department of Pediatrics Phramongkutklao Hospital during December 1, 2006 November 30,2007. The questionnaires were performedand collected at month 0 and month 12th. Results: Fifty-two thalassemic patients treated with iron chelating agentwere enrolled. There were 19 thalassemic patient treated with Deferiprone 17 with Desferioxamine and 16 with Deferasirox . The results show that the median (range) of total summary score of quality of life (QOL) in age groupabove  12, 8-12 and below 8 years are 86.95 (68-95),68.47 (41-86) and 69.56 (43-82) respectively, which significantdifferences (p= 0.023).  For psychosocial health score especially social part the QOL in above 12 8-12 and below 8years are 100 (60-100), 90 (35-100) and 60 (60-80) respectively (p = 0.012). There were no significant differences inother variables such as gender diagnosis and incomes. The data show that improvement of emotion functioningscores in patients at the first evaluation 70 (15-100) to 80 (30-100) at the second evaluation with statistical significant(p =0.013). However there was no improvement in the parent QOL. There were no significant differences of PedQLTM Generic Core Scales in the firsts and second evaluation in Desferoxamine and Deferasirox group. Conclusion: Deferiprone can improve total summary score of QOL and psychological aspect especially emotion. Theolder patients have better quality of life than younger.